Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| AMD | Digital Realty Trust | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow AMD's FY2025 10-K documents real but bounded advantages: approximately 7,200 U.S. patents and roughly 18,900 patent matters worldwide, an outright claim that 'We are the market share leader in semi-custom game console products,' and gross margin of 50% on revenue up 34% to $34.6 billion. The same filing sets the ceiling: 'Some of our competitors may possess stronger market positions, larger customer bases, more design wins, and greater financial, sales, marketing, and distribution resources than us'; Nvidia is named 'the discrete GPU market share leader'; and AMD relies on TSMC 'for the production of all wafers for microprocessor and GPU products at 7 nanometer (nm) or smaller nodes.' Advantages that are genuine, contested, and dependent on a shared foundry are narrow, not wide. | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | intangibles ip The FY2025 10-K locates the durable asset in design IP rather than manufacturing: 'We rely on contracts and intellectual property rights to protect our products and technologies from unauthorized third-party copying and use,' with approximately 7,200 U.S. patents and about 18,900 patent matters worldwide spanning x86 EPYC/Ryzen CPUs, CDNA/RDNA graphics and the Versal/Zynq adaptive-SoC families, and it credits customer wins to 'our broad IP portfolio and leadership in design, integration and advanced packaging.' It is explicitly not cost_scale: AMD is fabless and 'utilize[s] Taiwan Semiconductor Manufacturing Company Limited (TSMC) for the production of wafers' — the same leading-edge foundry its merchant competitors use, so no manufacturing-scale advantage accrues to it. | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | fast follower The FY2025 10-K itself places AMD behind the pace-setter in its two most important markets: 'Our principal competitor in the supply of discrete graphics is Nvidia, who is the discrete GPU market share leader,' and the risk factors state Nvidia 'leverages its market position in data center GPU, financial resources, and proprietary software ecosystem to promote its systems and influences customers who do business with us.' AMD is nonetheless executing 'an annual cadence of leadership for AMD Instinct solutions' and has won gigawatt-scale commitments (OpenAI, 6 GW) — following fast and closely, not setting the pace. | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | moderate FY2025 gross margin was 50%, up from 49% in 2024 per the 10-K — healthy and improving — but the same filing attributes average-selling-price pressure to competitors: Intel 'uses its microprocessor market position to price its products aggressively and target our customers and channel partners with special incentives. These aggressive activities have reduced and may reduce our unit sales and average selling prices for many of our products'. Pricing power is real but contested. | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | AMD's edge is architectural design IP executed on someone else's fabs. The FY2025 10-K describes a full-stack portfolio — EPYC server CPUs, Instinct AI accelerators, Ryzen client parts where 'AMD was the first company to integrate a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs,' Radeon graphics, Pensando networking and Versal adaptive SoCs — backed by roughly 18,900 patent matters worldwide, and it discloses gigawatt-scale customer commitments (an October 2025 agreement with OpenAI 'to deploy 6 gigawatts of AMD GPUs,' first gigawatt on Instinct MI450). The same filing bounds that moat: Nvidia is 'the discrete GPU market share leader' and 'leverages its market position in data center GPU, financial resources, and proprietary software ecosystem'; Intel 'uses its microprocessor market position to price its products aggressively'; Arm architectures and customers who 'internally develop products to support similar AI workloads' are named as encroaching; and every wafer at 7 nm or below comes from TSMC. Revenue grew 34% in FY2025 with Data Center up 32%, but the filing's own competitive framing places AMD in the challenger seat rather than the entrenched one. | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | A fabless merchant-silicon designer sitting one layer above the foundries: the FY2025 10-K states AMD relies on TSMC 'for the production of all wafers for microprocessor and GPU products at 7 nanometer (nm) or smaller nodes' and primarily on GLOBALFOUNDRIES above 7 nm, with packaging and test performed by Asia-Pacific ATMP partners — so its cost, supply and cadence are inherited from partners it does not control. | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |